ArticleDiscover nano2026
Computational and experimental study of CuO-ZnO nanocomposite using the plant Peganum harmala L. and their antifungal, antibacterial applications.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid emergence of AMR necessitates the development of novel, sustainable therapeutic agents. This study reports the green synthesis of copper-decorated zinc oxide (CuO-ZnO) nanocomposite using an aqueous leaf extract of Peganum harmala L., which served as a reducing and capping agent. A quantitative EDX analysis confirmed a high loading of Cu of 24.25% (7.09%) mass. Characterization showed that the average primary particle size was 29 ± 1.3 nm, and that the structures were crystalline and hexagonal, known as wurtzite. The nanocomposite exhibited a positive zeta potential of + 47.2 ± 4.24 mV, indicating good colloidal stability. A typical absorption peak at 372 nm was observed using UV-visible spectroscopy. The CuO-ZnO nanocomposite showed significant dose-dependent antibacterial activity with Minimum Inhibitory Concentrations (MIC) of 50 µg/mL, 70 µg/mL, and 80 µg/mL for Staphylococcus epidermidis, Salmonella typhi, and Klebsiella pneumoniae, respectively. The synthesized CuO-ZnO nanocomposite exhibited significant antifungal activity, inhibiting the linear growth of Aspergillus flavus and Fusarium oxysporum by 87.67 mm and 74.33 mm, respectively. While computational models suggest localized structural integration, the system is described as a copper-decorated zinc oxide network, pending high-resolution phase-state verification. This integrated study highlights the potential of P. harmala-mediated CuO-ZnO nanocomposite as an eco-friendly antimicrobial agent for biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.